Explore this site to learn about MVID, patient resources, our research and future work towards a new therapy.What is MVID
New research and comprehensive resources for patients with microvillus inclusion disease
Microvillus inclusion disease (MVID) is a rare, genetic disease that causes chronic diarrhea in young babies. The amount of diarrhea often exceeds that of cholera, and infants will die unless they are given appropriate and often massive amounts of intravenous fluid. Patients with MVID often survive solely on IV fluids, also known as total parenteral nutrition or TPN, or they must undergo a small bowel transplant. Learn more about MVID.
At Vanessa Research we have patented and will soon begin clinical trials of a drug that has been developed to treat MVID – a treatment that will eliminate life-threatening diarrhea by encouraging immature cells in the intestine to grow normally and restore the absorption of fluids and nutrients. Learn more about our research.
Addressing the Microvillus Inclusion Disease Knowledge GapA Comprehensive Case Analysis Read more
Learn more about
Vanessa Research brings awareness of Microvillus Inclusion Disease to healthcare professionals worldwide HAMDEN, CT, May 8, 2019 — Vanessa Research, Inc. (VRI) — a biomedical company transforming the healthcare landscape by developing and commercializing innovative products in areas of unmet medical needs — participated in an interview with Health Professional Radio (HPR), a health-dedicated media…
Vanessa Research brings cutting-edge science to the world-renowned pediatric congress Vanessa Research, Inc. (VRI) — a biomedical company that is transforming the healthcare landscape through the development of innovative products and solutions in areas of unmet medical needs — announced it will be a silver sponsor of the 17th Congress of the European Society for…
Hamden, CT – Vanessa Research, Inc. (VRI) is pleased to announce that its MIDA™ (Microvillus Inclusion Disease Assay) project, under the direction of Dr. Ludmila Kvochina, has been accepted into the 2019 cohort of the highly selective Accelerator for Biosciences in Connecticut (ABCT). MIDA™ is the first-ever dipstick test developed to screen for the incredibly…